Resources

Notification fatigue is reshaping caregiver engagement. Behavioral intelligence helps identify when caregiver support can have the greatest impact.

See how behavioral intelligence helps pharmaceutical organizations improve oncology adherence, patient engagement, and long-term treatment persistence.

Explore how memory, routine, and patient behavior influence neurology adherence and discover new strategies to improve engagement and long-term persistence.

Learn how dynamic, personalized support, through Medisafe's Digital Drug Companion, is reshaping adherence across complex biologic therapies and closing gaps in traditional patient programs.

Discover how an IQVIA study found Digital Companion users were significantly more likely to remain on therapy, providing new evidence for the impact of digital patient support.

From routine disruptions to symptom management, discover the factors that shape gastroenterology therapy persistence.

Nearly 30% of missed doses occur because patients don't believe treatment is necessary. Explore the behavioral drivers behind dermatology adherence.

New analysis of 12+ years of adherence data reveals the behavioral patterns, treatment factors, and support mechanisms that drive metabolic therapy persistence.

New analysis of millions of managed doses uncovers the behavioral patterns, treatment complexities, and engagement trends shaping cardiovascular therapy persistence.

Routine disruptions, affordability, and patient behavior all influence medication adherence. Smarter digital support helps address the root causes of non-adherence.

Breast cancer remains one of the most prevalent malignancies worldwide, with an estimated 287,850 new invasive cases and 43,250 breast cancer–related deaths projected in the United States in 2025 (American Cancer Society, 2025). Despite advances in targeted oral therapies for extended adjuvant treatment, real‐world studies find that up to 50% of patients discontinue or skip doses, undermining efficacy (Mayo Clinic, 2024).

Multiple Sclerosis (MS) represents a formidable challenge in healthcare, a chronic, often unpredictable disease of the central nervous system that impacts millions worldwide. Its complex nature demands not just cutting-edge therapies but also robust, sustained patient support to navigate the daily realities of living with the condition.

Medication non-adherence is a $300B issue that can impact the cost of prescription drugs, medical care, and lead to serious health risks. Unfortunately, without greater support, non-adherence can become commonplace especially among patients with chronic disease. But medication non-adherence is more than just skipping a dose or forgetting a refill.

Here’s what today’s pricing development means for pharma brand marketers, patient support teams, innovation leads, access executives, and procurement leadership—and how Medisafe is uniquely positioned to drive higher adherence, long-term engagement, and ultimately better outcomes for those embarking on complex treatment journeys.

For the 133 million Americans who live with a chronic condition, and the 81 million who have two or more conditions, managing medications is more than just taking a pill. It becomes a priority to maintaining good health and the ability to live an active and fulfilling life.

Leading pharmaceutical companies are now using AI to help healthcare providers simplify and streamline the patient experience for specialty medications, which can be difficult to access, adhere to, and afford.

A cure mindset changes everything. That’s the animating force behind our conversation with Beth Dean, CEO of CURE Epilepsy, as we unpack how a parent-founded nonprofit reframed a field long focused on treatments and built a pipeline that backs bold science, supports families, and accelerates breakthroughs.

Medisafe’s real-world data shows that more than half of patients taking the most-prescribed antiplatelet meds have missed 1 to 5+ consecutive doses, leaving some untreated and at a greater risk of thrombosis and other complications.